Adrenomed develops a first-in-class monoclonal antibody (Adrecizumab) that targets the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock.
Confo utilizes pioneering G protein-coupled receptor (GPCR) technology to build up a portfolio of first-in-class programs addressing difficult-to-drug disease targets in high need indications in neurology and beyond.
Location: Belgium
Wellington contact: Marianne Mertens, Regina Hodits
Creative Balloons develops and markets novel catheter technology based on microscopically thin, complex shaped balloon films made of polyurethane (PUR).
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.
Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.
ImCheck Therapeutics develops antibody-based therapeutics targeting a novel class of immunomodulators (butyrophilins), with primary focus on activating a yet unexploited population of immune cells (γδ T-cells) for the treatment of cancer.
ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.
Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.
Koa Health is a digital mental healthcare provider redefining care by offering a range of personalised mental health solutions backed by science and designed to improve user wellbeing.
NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.
Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.
Polares Medical develops a novel mitral valve repair system which can be implanted minimally invasively. Polares Medical was created as a spin-off of Symetis.
Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.
SidekickHealth develops gamified digital therapeutic solutions to supports people with chronic diseases. The company operates a patient centric digital care platform.
SIRS develops a fibrin-derived peptide (FX06) for the treatment of diseases related to vascular leakage e.g., ARDS in patients with underlying COVID-19 infection.
STipe Therapeutics is developing first-in-class drugs targeting intracellular protein-protein interactions of the STING pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders.
SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.
Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.
